Amylyx Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 26, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	1,676	257	994	2,448	-	-
Market Cap Growth	558.15%	-74.11%	-59.40%	-	-	-
Enterprise Value	1,338	26	644	2,292	-	-
Last Close Price	15.26	3.78	14.72	36.95	-	-
PE Ratio	-	-	20.17	-	-	-
Forward PE	-	-	16.68	-	-	-
PS Ratio	-2520.07	2.95	2.61	110.13	-	-
PB Ratio	5.05	1.56	2.29	7.19	-	-
P/TBV Ratio	5.05	1.56	2.29	7.19	-	-
P/FCF Ratio	-	-	93.08	-	-	-
P/OCF Ratio	-	-	83.39	-	-	-
EV/Sales Ratio	-	0.29	1.69	103.12	-	-
EV/EBITDA Ratio	-	-	16.13	-	-	-
EV/EBIT Ratio	-	-	16.59	-	-	-
EV/FCF Ratio	-	-	60.27	-	-	-
Debt / Equity Ratio	0.02	0.01	0.01	0.02	-	0.27
Debt / EBITDA Ratio	-	-	0.10	-	-	-
Debt / FCF Ratio	-	-	0.40	-	-	-
Net Debt / Equity Ratio	-1.02	-1.06	-0.85	-1.00	-1.09	-2.15
Net Debt / EBITDA Ratio	1.75	0.60	-9.20	1.70	1.16	0.29
Net Debt / FCF Ratio	1.77	0.86	-34.38	1.87	1.28	0.31
Asset Turnover	-	0.25	0.84	0.09	0.01	0.08
Inventory Turnover	-	-	6.39	-	-	-
Quick Ratio	13.35	6.23	5.02	7.78	5.53	1.76
Current Ratio	13.70	6.67	5.66	8.20	6.03	1.86
Return on Equity (ROE)	-56.53%	-100.88%	12.73%	-92.53%	-188.05%	-
Return on Assets (ROA)	-39.44%	-51.31%	5.34%	-50.63%	-86.34%	-281.44%
Return on Invested Capital (ROIC)	-	-1032.25%	106.30%	-	-	-
Return on Capital Employed (ROCE)	-57.40%	-176.70%	8.90%	-58.40%	-93.70%	-575.50%
Earnings Yield	-8.91%	-117.25%	4.96%	-8.10%	-	-
FCF Yield	-11.38%	-79.27%	1.07%	-7.45%	-	-
Buyback Yield / Dilution	-24.05%	2.64%	-19.65%	-788.13%	-8.37%	-3.20%

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q